Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting

Clin Pharmacol Ther. 2021 Aug;110(2):285-288. doi: 10.1002/cpt.2151. Epub 2021 Feb 16.

Abstract

Patients with multiple chronic conditions, including more advanced chronic kidney disease (CKD), are often excluded from clinical trials, creating challenges in deriving appropriate dosing information and labeling. This article summarizes the May 7, 2019, US Food and Drug Administration Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting, which solicited expert opinions on how to enroll patients with more advanced CKD into clinical trials as well as the assumptions behind and different approaches of exposure-matching.

MeSH terms

  • Advisory Committees / organization & administration*
  • Advisory Committees / standards
  • Area Under Curve
  • Clinical Trials as Topic / organization & administration*
  • Clinical Trials as Topic / standards
  • Drug Dosage Calculations
  • Half-Life
  • Kidney Diseases / epidemiology
  • Kidney Diseases / metabolism*
  • Multiple Chronic Conditions / epidemiology
  • Pharmacology, Clinical / organization & administration*
  • Pharmacology, Clinical / standards
  • United States
  • United States Food and Drug Administration / organization & administration*
  • United States Food and Drug Administration / standards